{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T23:55:32Z","timestamp":1790898932578,"version":"4.1.0"},"reference-count":96,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Hematol Malig Rep"],"DOI":"10.1007\/s11899-026-00789-y","type":"journal-article","created":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T10:31:45Z","timestamp":1790850705000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["FLT3-Mutated AML: Transplanting with Precision in the Targeted Era"],"prefix":"10.1007","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5168-4030","authenticated-orcid":false,"given":"Joseph F.","family":"Mort","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0855-9653","authenticated-orcid":false,"given":"Alex J.","family":"Ambinder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,1]]},"reference":[{"issue":"22","key":"789_CR1","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1056\/NEJMoa1301689","volume":"368","author":"N Research","year":"2013","unstructured":"Cancer Genome Atlas, Research N, Ley TJ, Miller C, Ding L, Raphael BJ, Mungall AJ, et al. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med. 2013;368(22):2059\u201374.","journal-title":"N Engl J Med"},{"issue":"8","key":"789_CR2","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1038\/leu.2014.55","volume":"28","author":"R Kihara","year":"2014","unstructured":"Kihara R, Nagata Y, Kiyoi H, Kato T, Yamamoto E, Suzuki K, et al. Comprehensive analysis of genetic alterations and their prognostic impacts in adult acute myeloid leukemia patients. Leukemia. 2014;28(8):1586\u201395.","journal-title":"Leukemia"},{"issue":"23","key":"789_CR3","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","volume":"374","author":"E Papaemmanuil","year":"2016","unstructured":"Papaemmanuil E, Gerstung M, Bullinger L, Gaidzik VI, Paschka P, Roberts ND, et al. Genomic Classification and Prognosis in Acute Myeloid Leukemia. N Engl J Med. 2016;374(23):2209\u201321.","journal-title":"N Engl J Med"},{"issue":"5","key":"789_CR4","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1182\/blood-2002-02-0492","volume":"100","author":"DG Gilliland","year":"2002","unstructured":"Gilliland DG, Griffin JD. The roles of FLT3 in hematopoiesis and leukemia. Blood. 2002;100(5):1532\u201342.","journal-title":"Blood"},{"issue":"2","key":"789_CR5","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1111\/cas.14274","volume":"111","author":"H Kiyoi","year":"2020","unstructured":"Kiyoi H, Kawashima N, Ishikawa Y. FLT3 mutations in acute myeloid leukemia: Therapeutic paradigm beyond inhibitor development. Cancer Sci. 2020;111(2):312\u201322.","journal-title":"Cancer Sci"},{"issue":"9","key":"789_CR6","first-page":"3074","volume":"93","author":"H Kiyoi","year":"1999","unstructured":"Kiyoi H, Naoe T, Nakano Y, Yokota S, Minami S, Miyawaki S, et al. Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia. Blood. 1999;93(9):3074\u201380.","journal-title":"Blood"},{"issue":"8","key":"789_CR7","doi-asserted-by":"publisher","first-page":"2434","DOI":"10.1182\/blood.V97.8.2434","volume":"97","author":"Y Yamamoto","year":"2001","unstructured":"Yamamoto Y, Kiyoi H, Nakano Y, Suzuki R, Kodera Y, Miyawaki S, et al. Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. Blood. 2001;97(8):2434\u20139.","journal-title":"Blood"},{"issue":"6","key":"789_CR8","doi-asserted-by":"publisher","first-page":"1752","DOI":"10.1182\/blood.V98.6.1752","volume":"98","author":"PD Kottaridis","year":"2001","unstructured":"Kottaridis PD, Gale RE, Frew ME, Harrison G, Langabeer SE, Belton AA, et al. The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood. 2001;98(6):1752\u20139.","journal-title":"Blood"},{"issue":"12","key":"789_CR9","doi-asserted-by":"publisher","first-page":"4326","DOI":"10.1182\/blood.V99.12.4326","volume":"99","author":"C Thiede","year":"2002","unstructured":"Thiede C, Steudel C, Mohr B, Schaich M, Schakel U, Platzbecker U, et al. Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood. 2002;99(12):4326\u201335.","journal-title":"Blood"},{"issue":"1","key":"789_CR10","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1182\/blood.V100.1.59","volume":"100","author":"S Schnittger","year":"2002","unstructured":"Schnittger S, Schoch C, Dugas M, Kern W, Staib P, Wuchter C, et al. Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease. Blood. 2002;100(1):59\u201366.","journal-title":"Blood"},{"issue":"1","key":"789_CR11","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1111\/j.1365-2141.2011.08577.x","volume":"153","author":"R Riccioni","year":"2011","unstructured":"Riccioni R, Pelosi E, Riti V, Castelli G, Lo-Coco F, Testa U. Immunophenotypic features of acute myeloid leukaemia patients exhibiting high FLT3 expression not associated with mutations. Br J Haematol. 2011;153(1):33\u201342.","journal-title":"Br J Haematol"},{"issue":"3","key":"789_CR12","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1182\/blood.V87.3.1089.bloodjournal8731089","volume":"87","author":"CE Carow","year":"1996","unstructured":"Carow CE, Levenstein M, Kaufmann SH, Chen J, Amin S, Rockwell P, et al. Expression of the hematopoietic growth factor receptor FLT3 (STK-1\/Flk2) in human leukemias. Blood. 1996;87(3):1089\u201396.","journal-title":"Blood"},{"key":"789_CR13","doi-asserted-by":"publisher","first-page":"612880","DOI":"10.3389\/fonc.2020.612880","volume":"10","author":"VE Kennedy","year":"2020","unstructured":"Kennedy VE, Smith CC. FLT3 Mutations in Acute Myeloid Leukemia: Key Concepts and Emerging Controversies. Front Oncol. 2020;10:612880.","journal-title":"Front Oncol"},{"issue":"12","key":"789_CR14","doi-asserted-by":"publisher","first-page":"3286","DOI":"10.1182\/blood-2010-01-266742","volume":"117","author":"T Sato","year":"2011","unstructured":"Sato T, Yang X, Knapper S, White P, Smith BD, Galkin S, et al. FLT3 ligand impedes the efficacy of FLT3 inhibitors in vitro and in vivo. Blood. 2011;117(12):3286\u201393.","journal-title":"Blood"},{"issue":"26","key":"789_CR15","doi-asserted-by":"publisher","first-page":"6987","DOI":"10.1182\/blood-2011-03-340273","volume":"117","author":"M Levis","year":"2011","unstructured":"Levis M. FLT3\/ITD AML and the law of unintended consequences. Blood. 2011;117(26):6987\u201390.","journal-title":"Blood"},{"issue":"22","key":"789_CR16","doi-asserted-by":"publisher","first-page":"2349","DOI":"10.1001\/jama.2009.813","volume":"301","author":"J Koreth","year":"2009","unstructured":"Koreth J, Schlenk R, Kopecky KJ, Honda S, Sierra J, Djulbegovic BJ, et al. Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials. JAMA. 2009;301(22):2349\u201361.","journal-title":"JAMA"},{"issue":"4","key":"789_CR17","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1001\/jamaoncol.2022.7605","volume":"9","author":"M Bornhauser","year":"2023","unstructured":"Bornhauser M, Schliemann C, Schetelig J, Rollig C, Kramer M, Glass B, et al. Allogeneic Hematopoietic Cell Transplantation vs Standard Consolidation Chemotherapy in Patients With Intermediate-Risk Acute Myeloid Leukemia: A Randomized Clinical Trial. JAMA Oncol. 2023;9(4):519\u201326.","journal-title":"JAMA Oncol"},{"issue":"1","key":"789_CR18","doi-asserted-by":"publisher","first-page":"68","DOI":"10.3324\/haematol.2024.285879","volume":"110","author":"D Niederwieser","year":"2025","unstructured":"Niederwieser D, Hasenclever D, Berdel WE, Biemond BJ, Al-Ali H, Chalandon Y, et al. Hematopoietic cell transplantation for older acute myeloid leukemia patients in first complete remission: results of a randomized phase III study. Haematologica. 2025;110(1):68\u201377.","journal-title":"Haematologica"},{"issue":"7","key":"789_CR19","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1038\/sj.leu.2404246","volume":"20","author":"J Cloos","year":"2006","unstructured":"Cloos J, Goemans BF, Hess CJ, van Oostveen JW, Waisfisz Q, Corthals S, et al. Stability and prognostic influence of FLT3 mutations in paired initial and relapsed AML samples. Leukemia. 2006;20(7):1217\u201320.","journal-title":"Leukemia"},{"issue":"5","key":"789_CR20","doi-asserted-by":"publisher","first-page":"2776","DOI":"10.1182\/blood-2007-08-109090","volume":"111","author":"RE Gale","year":"2008","unstructured":"Gale RE, Green C, Allen C, Mead AJ, Burnett AK, Hills RK, et al. The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia. Blood. 2008;111(5):2776\u201384.","journal-title":"Blood"},{"issue":"4","key":"789_CR21","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1182\/blood-2006-04-015826","volume":"110","author":"AJ Mead","year":"2007","unstructured":"Mead AJ, Linch DC, Hills RK, Wheatley K, Burnett AK, Gale RE. FLT3 tyrosine kinase domain mutations are biologically distinct from and have a significantly more favorable prognosis than FLT3 internal tandem duplications in patients with acute myeloid leukemia. Blood. 2007;110(4):1262\u201370.","journal-title":"Blood"},{"issue":"10","key":"789_CR22","doi-asserted-by":"publisher","first-page":"2506","DOI":"10.3324\/haematol.2022.281218","volume":"107","author":"TB Polak","year":"2022","unstructured":"Polak TB, Van Rosmalen J, Dirven S, Herzig JK, Cloos J, Meshinchi S, et al. Association of FLT3-internal tandem duplication length with overall survival in acute myeloid leukemia: a systematic review and meta-analysis. Haematologica. 2022;107(10):2506\u201310.","journal-title":"Haematologica"},{"issue":"10","key":"789_CR23","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1002\/gcc.21975","volume":"51","author":"S Schnittger","year":"2012","unstructured":"Schnittger S, Bacher U, Haferlach C, Alpermann T, Kern W, Haferlach T. Diversity of the juxtamembrane and TKD1 mutations (exons 13\u201315) in the FLT3 gene with regards to mutant load, sequence, length, localization, and correlation with biological data. Genes Chromosomes Cancer. 2012;51(10):910\u201324.","journal-title":"Genes Chromosomes Cancer"},{"issue":"14","key":"789_CR24","doi-asserted-by":"publisher","first-page":"2734","DOI":"10.1182\/blood-2012-06-431122","volume":"121","author":"M Pratcorona","year":"2013","unstructured":"Pratcorona M, Brunet S, Nomdedeu J, Ribera JM, Tormo M, Duarte R, et al. Favorable outcome of patients with acute myeloid leukemia harboring a low-allelic burden FLT3-ITD mutation and concomitant NPM1 mutation: relevance to post-remission therapy. Blood. 2013;121(14):2734\u20138.","journal-title":"Blood"},{"issue":"23","key":"789_CR25","doi-asserted-by":"publisher","first-page":"3441","DOI":"10.1182\/blood-2014-05-578070","volume":"124","author":"RF Schlenk","year":"2014","unstructured":"Schlenk RF, Kayser S, Bullinger L, Kobbe G, Casper J, Ringhoffer M, et al. Differential impact of allelic ratio and insertion site in FLT3-ITD-positive AML with respect to allogeneic transplantation. Blood. 2014;124(23):3441\u20139.","journal-title":"Blood"},{"issue":"4","key":"789_CR26","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","volume":"129","author":"H Dohner","year":"2017","unstructured":"Dohner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Buchner T, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129(4):424\u201347.","journal-title":"Blood"},{"issue":"5","key":"789_CR27","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1182\/blood.2019002697","volume":"135","author":"K Dohner","year":"2020","unstructured":"Dohner K, Thiede C, Jahn N, Panina E, Gambietz A, Larson RA, et al. Impact of NPM1\/FLT3-ITD genotypes defined by the 2017 European LeukemiaNet in patients with acute myeloid leukemia. Blood. 2020;135(5):371\u201380.","journal-title":"Blood"},{"issue":"7","key":"789_CR28","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1016\/j.bbmt.2016.03.027","volume":"22","author":"B Oran","year":"2016","unstructured":"Oran B, Cortes J, Beitinjaneh A, Chen HC, de Lima M, Patel K, et al. Allogeneic Transplantation in First Remission Improves Outcomes Irrespective of FLT3-ITD Allelic Ratio in FLT3-ITD-Positive Acute Myelogenous Leukemia. Biol Blood Marrow Transpl. 2016;22(7):1218\u201326.","journal-title":"Biol Blood Marrow Transpl"},{"issue":"20","key":"789_CR29","doi-asserted-by":"publisher","first-page":"2744","DOI":"10.1182\/bloodadvances.2018020305","volume":"2","author":"M Sakaguchi","year":"2018","unstructured":"Sakaguchi M, Yamaguchi H, Najima Y, Usuki K, Ueki T, Oh I, et al. Prognostic impact of low allelic ratio FLT3-ITD and NPM1 mutation in acute myeloid leukemia. Blood Adv. 2018;2(20):2744\u201354.","journal-title":"Blood Adv"},{"issue":"7","key":"789_CR30","first-page":"456","volume":"29","author":"C Zhou","year":"2023","unstructured":"Zhou C, Zheng F, Xu L, Zhang X, Chang Y, Mo X, et al. FLT3-ITD Allelic Ratio and NPM1 Mutation Do Not Impact Outcomes in Acute Myeloid Leukemia Patients with FLT3-ITD after Allogeneic Hematopoietic Stem Cell Transplantation: A Retrospective Propensity Score- Matching Study. Transpl Cell Ther. 2023;29(7):456. e1- e11.","journal-title":"Transpl Cell Ther"},{"issue":"3","key":"789_CR31","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1002\/ajh.26451","volume":"97","author":"PK Reville","year":"2022","unstructured":"Reville PK, Sasaki K, Kantarjian HM, Daver NG, Yilmaz M, Dinardo CD, et al. Improved outcomes among newly diagnosed patients with FMS-like tyrosine kinase 3 internal tandem duplication mutated acute myeloid leukemia treated with contemporary therapy: Revisiting the European LeukemiaNet adverse risk classification. Am J Hematol. 2022;97(3):329\u201337.","journal-title":"Am J Hematol"},{"issue":"12","key":"789_CR32","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1182\/blood.2022016867","volume":"140","author":"H Dohner","year":"2022","unstructured":"Dohner H, Wei AH, Appelbaum FR, Craddock C, DiNardo CD, Dombret H, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022;140(12):1345\u201377.","journal-title":"Blood"},{"issue":"6","key":"789_CR33","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1016\/j.bbmt.2008.03.005","volume":"14","author":"L Luznik","year":"2008","unstructured":"Luznik L, O\u2019Donnell PV, Symons HJ, Chen AR, Leffell MS, Zahurak M, et al. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transpl. 2008;14(6):641\u201350.","journal-title":"Biol Blood Marrow Transpl"},{"issue":"8","key":"789_CR34","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1182\/blood-2015-04-639831","volume":"126","author":"SO Ciurea","year":"2015","unstructured":"Ciurea SO, Zhang MJ, Bacigalupo AA, Bashey A, Appelbaum FR, Aljitawi OS, et al. Haploidentical transplant with posttransplant cyclophosphamide vs matched unrelated donor transplant for acute myeloid leukemia. Blood. 2015;126(8):1033\u201340.","journal-title":"Blood"},{"issue":"12","key":"789_CR35","doi-asserted-by":"publisher","first-page":"1826","DOI":"10.1182\/bloodadvances.2019000050","volume":"3","author":"A Rashidi","year":"2019","unstructured":"Rashidi A, Hamadani M, Zhang MJ, Wang HL, Abdel-Azim H, Aljurf M, et al. Outcomes of haploidentical vs matched sibling transplantation for acute myeloid leukemia in first complete remission. Blood Adv. 2019;3(12):1826\u201336.","journal-title":"Blood Adv"},{"issue":"1","key":"789_CR36","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.bbmt.2014.10.002","volume":"21","author":"J Dehn","year":"2015","unstructured":"Dehn J, Buck K, Maiers M, Confer D, Hartzman R, Kollman C, et al. 8\/8 and 10\/10 high-resolution match rate for the be the match unrelated donor registry. Biol Blood Marrow Transpl. 2015;21(1):137\u201341.","journal-title":"Biol Blood Marrow Transpl"},{"key":"789_CR37","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s13045-016-0248-3","volume":"9","author":"MT Rubio","year":"2016","unstructured":"Rubio MT, Savani BN, Labopin M, Piemontese S, Polge E, Ciceri F, et al. Impact of conditioning intensity in T-replete haplo-identical stem cell transplantation for acute leukemia: a report from the acute leukemia working party of the EBMT. J Hematol Oncol. 2016;9:25.","journal-title":"J Hematol Oncol"},{"issue":"6","key":"789_CR38","first-page":"483","volume":"27","author":"BL Scott","year":"2021","unstructured":"Scott BL, Pasquini MC, Fei M, Fraser R, Wu J, Devine SM, et al. Myeloablative versus Reduced-Intensity Conditioning for Hematopoietic Cell Transplantation in Acute Myelogenous Leukemia and Myelodysplastic Syndromes-Long-Term Follow-Up of the BMT CTN 0901 Clinical Trial. Transpl Cell Ther. 2021;27(6):483. e1- e6.","journal-title":"Transpl Cell Ther"},{"key":"789_CR39","doi-asserted-by":"publisher","first-page":"708727","DOI":"10.3389\/fonc.2021.708727","volume":"11","author":"Y Song","year":"2021","unstructured":"Song Y, Yin Z, Ding J, Wu T. Reduced Intensity Conditioning Followed by Allogeneic Hematopoietic Stem Cell Transplantation Is a Good Choice for Acute Myeloid Leukemia and Myelodysplastic Syndrome: A Meta-Analysis of Randomized Controlled Trials. Front Oncol. 2021;11:708727.","journal-title":"Front Oncol"},{"issue":"10","key":"789_CR40","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.1038\/s41409-020-0868-7","volume":"55","author":"M Yanada","year":"2020","unstructured":"Yanada M, Fukuda T, Tanaka M, Ota S, Toya T, Mori T, et al. Long-term results of reduced-intensity conditioning allogeneic hematopoietic cell transplantation for older patients with acute myeloid leukemia: a retrospective analysis of 10-year follow-up data. Bone Marrow Transpl. 2020;55(10):2008\u201316.","journal-title":"Bone Marrow Transpl"},{"issue":"14","key":"789_CR41","doi-asserted-by":"publisher","first-page":"3495","DOI":"10.1182\/bloodadvances.2025015964","volume":"9","author":"S Abedin","year":"2025","unstructured":"Abedin S, Martens MJ, Bolanos-Meade J, Al Malki MM, Lian Q, Runaas L, et al. Impact of posttransplant cyclophosphamide-based GVHD prophylaxis in patients 70 years and older: an update from BMT CTN 1703. Blood Adv. 2025;9(14):3495\u2013501.","journal-title":"Blood Adv"},{"key":"789_CR42","doi-asserted-by":"publisher","first-page":"100990","DOI":"10.1016\/j.blre.2022.100990","volume":"62","author":"RJ Jones","year":"2023","unstructured":"Jones RJ, Bacigalupo A. The next horizon now that everyone has a donor: Precision allogeneic transplantation. Blood Rev. 2023;62:100990.","journal-title":"Blood Rev"},{"issue":"7","key":"789_CR43","first-page":"683","volume":"30","author":"BJ Pandya","year":"2024","unstructured":"Pandya BJ, Burns LJ, Wang T, Xie B, Touya M, Spalding J, et al. Clinical Outcomes and Treatment Patterns in Adults With FLT3-ITD(mut+) Acute Myeloid Leukemia Undergoing Allogeneic Hemopoietic Cell Transplantation in the United States and Canada. Transpl Cell Ther. 2024;30(7):683. e1- e13.","journal-title":"Transpl Cell Ther"},{"issue":"10","key":"789_CR44","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1038\/nrd2130","volume":"5","author":"S Wilhelm","year":"2006","unstructured":"Wilhelm S, Carter C, Lynch M, Lowinger T, Dumas J, Smith RA, et al. Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat Rev Drug Discov. 2006;5(10):835\u201344.","journal-title":"Nat Rev Drug Discov"},{"key":"789_CR45","doi-asserted-by":"crossref","unstructured":"Stone RM, Manley PW, Larson RA, Capdeville R. Midostaurin: its odyssey from discovery to approval for treating acute myeloid leukemia and advanced systemic mastocytosis. Blood Adv. 2017;2(4):444\u2013453. Blood Adv. 2018;2(7):787.","DOI":"10.1182\/bloodadvances.2018018481"},{"issue":"5","key":"789_CR46","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1056\/NEJMoa1614359","volume":"377","author":"RM Stone","year":"2017","unstructured":"Stone RM, Mandrekar SJ, Sanford BL, Laumann K, Geyer S, Bloomfield CD, et al. Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation. N Engl J Med. 2017;377(5):454\u201364.","journal-title":"N Engl J Med"},{"issue":"1","key":"789_CR47","first-page":"218","volume":"144","author":"R Stone","year":"2024","unstructured":"Stone R, Yin J, Mandrekar SJ, Benner A, Saadati M, Galinsky IA, et al. 10 year follow-up of CALGB 10603\/Ratify: midostaurin versus placebo plus intensive chemotherapy in newly diagnosed FLT3 mutant acute myeloid leukemia patients aged 18\u201360 years [abstract]. Blood_supplement. 2024;144(1):218.","journal-title":"Blood_supplement"},{"issue":"2","key":"789_CR48","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1038\/s41375-018-0357-9","volume":"33","author":"N Daver","year":"2019","unstructured":"Daver N, Schlenk RF, Russell NH, Levis MJ. Targeting FLT3 mutations in AML: review of current knowledge and evidence. Leukemia. 2019;33(2):299\u2013312.","journal-title":"Leukemia"},{"issue":"18","key":"789_CR49","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.1056\/NEJMoa1902688","volume":"381","author":"AE Perl","year":"2019","unstructured":"Perl AE, Martinelli G, Cortes JE, Neubauer A, Berman E, Paolini S, et al. Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML. N Engl J Med. 2019;381(18):1728\u201340.","journal-title":"N Engl J Med"},{"issue":"23","key":"789_CR50","doi-asserted-by":"publisher","first-page":"3366","DOI":"10.1182\/blood.2021011583","volume":"139","author":"AE Perl","year":"2022","unstructured":"Perl AE, Larson RA, Podoltsev NA, Strickland S, Wang ES, Atallah E, et al. Follow-up of patients with R\/R FLT3-mutation-positive AML treated with gilteritinib in the phase 3 ADMIRAL trial. Blood. 2022;139(23):3366\u201375.","journal-title":"Blood"},{"issue":"4","key":"789_CR51","first-page":"265","volume":"29","author":"AE Perl","year":"2023","unstructured":"Perl AE, Larson RA, Podoltsev NA, Strickland S, Wang ES, Atallah E, et al. Outcomes in Patients with FLT3-Mutated Relapsed\/ Refractory Acute Myelogenous Leukemia Who Underwent Transplantation in the Phase 3 ADMIRAL Trial of Gilteritinib versus Salvage Chemotherapy. Transpl Cell Ther. 2023;29(4):265. e1- e10.","journal-title":"Transpl Cell Ther"},{"issue":"11","key":"789_CR52","doi-asserted-by":"publisher","first-page":"943","DOI":"10.18632\/oncotarget.27489","volume":"11","author":"T Aikawa","year":"2020","unstructured":"Aikawa T, Togashi N, Iwanaga K, Okada H, Nishiya Y, Inoue S, et al. Quizartinib, a selective FLT3 inhibitor, maintains antileukemic activity in preclinical models of RAS-mediated midostaurin-resistant acute myeloid leukemia cells. Oncotarget. 2020;11(11):943\u201355.","journal-title":"Oncotarget"},{"issue":"10388","key":"789_CR53","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1016\/S0140-6736(23)00464-6","volume":"401","author":"HP Erba","year":"2023","unstructured":"Erba HP, Montesinos P, Kim HJ, Patkowska E, Vrhovac R, Zak P, et al. Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023;401(10388):1571\u201383.","journal-title":"Lancet"},{"issue":"S3","key":"789_CR54","doi-asserted-by":"publisher","first-page":"e446548","DOI":"10.1097\/01.HS9.0000968840.44654.8f","volume":"7","author":"MJ Levis","year":"2023","unstructured":"Levis MJ, Erba HP, Montesinos P, Vrhovac R, Patkowska E, Kim H-J, et al. P483: QUANTUM-FIRST TRIAL: FLT3-ITD\u2013SPECIFIC MEASURABLE RESIDUAL DISEASE (MRD) CLEARANCE IS ASSOCIATED WITH IMPROVED OVERALL SURVIVAL. HemaSphere. 2023;7(S3):e446548.","journal-title":"HemaSphere"},{"issue":"9","key":"789_CR55","doi-asserted-by":"publisher","first-page":"2024","DOI":"10.3324\/haematol.2024.286623","volume":"110","author":"RF Schlenk","year":"2025","unstructured":"Schlenk RF, Montesinos P, Kim HJ, Romero-Aguilar A, Vrhovac R, Patkowska E, et al. Impact of hematopoietic cell transplantation and quizartinib in newly diagnosed patients with acute myeloid leukemia and FMS-like tyrosine kinase 3-internal tandem duplications in the QuANTUM-First trial. Haematologica. 2025;110(9):2024\u201339.","journal-title":"Haematologica"},{"issue":"7","key":"789_CR56","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa2012971","volume":"383","author":"CD DiNardo","year":"2020","unstructured":"DiNardo CD, Jonas BA, Pullarkat V, Thirman MJ, Garcia JS, Wei AH, et al. Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia. N Engl J Med. 2020;383(7):617\u201329.","journal-title":"N Engl J Med"},{"issue":"4","key":"789_CR57","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1002\/ajh.27246","volume":"99","author":"KW Pratz","year":"2024","unstructured":"Pratz KW, Jonas BA, Pullarkat V, Thirman MJ, Garcia JS, Dohner H, et al. Long-term follow-up of VIALE-A: Venetoclax and azacitidine in chemotherapy-ineligible untreated acute myeloid leukemia. Am J Hematol. 2024;99(4):615\u201324.","journal-title":"Am J Hematol"},{"issue":"13","key":"789_CR58","doi-asserted-by":"publisher","first-page":"2744","DOI":"10.1158\/1078-0432.CCR-21-3405","volume":"28","author":"M Konopleva","year":"2022","unstructured":"Konopleva M, Thirman MJ, Pratz KW, Garcia JS, Recher C, Pullarkat V, et al. Impact of FLT3 Mutation on Outcomes after Venetoclax and Azacitidine for Patients with Treatment-Naive Acute Myeloid Leukemia. Clin Cancer Res. 2022;28(13):2744\u201352.","journal-title":"Clin Cancer Res"},{"issue":"21","key":"789_CR59","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1182\/blood.2024025409","volume":"144","author":"H Dohner","year":"2024","unstructured":"Dohner H, DiNardo CD, Appelbaum FR, Craddock C, Dombret H, Ebert BL, et al. Genetic risk classification for adults with AML receiving less-intensive therapies: the 2024 ELN recommendations. Blood. 2024;144(21):2169\u201373.","journal-title":"Blood"},{"issue":"4","key":"789_CR60","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.3324\/haematol.2019.244020","volume":"106","author":"RS Mali","year":"2021","unstructured":"Mali RS, Zhang Q, DeFilippis RA, Cavazos A, Kuruvilla VM, Raman J, et al. Venetoclax combines synergistically with FLT3 inhibition to effectively target leukemic cells in FLT3-ITD+ acute myeloid leukemia models. Haematologica. 2021;106(4):1034\u201346.","journal-title":"Haematologica"},{"issue":"13","key":"789_CR61","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1200\/JCO.23.01911","volume":"42","author":"NJ Short","year":"2024","unstructured":"Short NJ, Daver N, Dinardo CD, Kadia T, Nasr LF, Macaron W, et al. Azacitidine, Venetoclax, and Gilteritinib in Newly Diagnosed and Relapsed or Refractory FLT3-Mutated AML. J Clin Oncol. 2024;42(13):1499\u2013508.","journal-title":"J Clin Oncol"},{"issue":"5","key":"789_CR62","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1038\/s41408-022-00670-0","volume":"12","author":"M Yilmaz","year":"2022","unstructured":"Yilmaz M, Kantarjian H, Short NJ, Reville P, Konopleva M, Kadia T, et al. Hypomethylating agent and venetoclax with FLT3 inhibitor triplet therapy in older\/unfit patients with FLT3 mutated AML. Blood Cancer J. 2022;12(5):77.","journal-title":"Blood Cancer J"},{"issue":"4","key":"789_CR63","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.3324\/haematol.2025.288553","volume":"111","author":"NJ Short","year":"2026","unstructured":"Short NJ, Loghavi S, Yilmaz M, Karrar O, Kim K, DiNnardo CD, et al. Long-term outcomes in FLT3-mutated acute myeloid leukemia after frontline hypomethylating agent, venetoclax and a FLT3 inhibitor. Haematologica. 2026;111(4):1246\u201353.","journal-title":"Haematologica"},{"issue":"1","key":"789_CR64","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1007\/s12185-024-03840-x","volume":"121","author":"M Sawa","year":"2025","unstructured":"Sawa M, Miyamoto T, Kim HJ, Hiramatsu Y, Cheong JW, Ikezoe T, et al. A phase 1\/2 study of gilteritinib in combination with chemotherapy in newly diagnosed patients with AML in Asia. Int J Hematol. 2025;121(1):56\u201367.","journal-title":"Int J Hematol"},{"issue":"16_suppl","key":"789_CR65","doi-asserted-by":"publisher","first-page":"6504","DOI":"10.1200\/JCO.2026.44.16_suppl.6504","volume":"44","author":"M Yilmaz","year":"2026","unstructured":"Yilmaz M, Muftuoglu M, DiNardo C, Kadia T, Konopleva M, Chan O, et al. Quizartinib in combination with decitabine and venetoclax for newly diagnosed and relapsed\/refractory FLT3-mutated AML. J Clin Oncol. 2026;44(16_suppl):6504.","journal-title":"J Clin Oncol."},{"issue":"4","key":"789_CR66","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1111\/joim.12720","volume":"283","author":"C Craddock","year":"2018","unstructured":"Craddock C, Versluis J, Labopin M, Socie G, Huynh A, Deconinck E, et al. Distinct factors determine the kinetics of disease relapse in adults transplanted for acute myeloid leukaemia. J Intern Med. 2018;283(4):371\u20139.","journal-title":"J Intern Med"},{"issue":"4","key":"789_CR67","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1038\/bmt.2015.170","volume":"51","author":"Y Song","year":"2016","unstructured":"Song Y, Magenau J, Li Y, Braun T, Chang L, Bixby D, et al. FLT3 mutational status is an independent risk factor for adverse outcomes after allogeneic transplantation in AML. Bone Marrow Transpl. 2016;51(4):511\u201320.","journal-title":"Bone Marrow Transpl"},{"issue":"5","key":"789_CR68","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1038\/s41409-022-01619-4","volume":"57","author":"Z Zhang","year":"2022","unstructured":"Zhang Z, Hasegawa Y, Hashimoto D, Senjo H, Kikuchi R, Chen X, et al. Gilteritinib enhances graft-versus-leukemia effects against FLT3-ITD mutant leukemia after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transpl. 2022;57(5):775\u201380.","journal-title":"Bone Marrow Transpl"},{"issue":"3","key":"789_CR69","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1038\/nm.4484","volume":"24","author":"NR Mathew","year":"2018","unstructured":"Mathew NR, Baumgartner F, Braun L, O\u2019Sullivan D, Thomas S, Waterhouse M, et al. Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells. Nat Med. 2018;24(3):282\u201391.","journal-title":"Nat Med"},{"issue":"26","key":"789_CR70","doi-asserted-by":"publisher","first-page":"2993","DOI":"10.1200\/JCO.19.03345","volume":"38","author":"A Burchert","year":"2020","unstructured":"Burchert A, Bug G, Fritz LV, Finke J, Stelljes M, Rollig C, et al. Sorafenib Maintenance After Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia With FLT3-Internal Tandem Duplication Mutation (SORMAIN). J Clin Oncol. 2020;38(26):2993\u20133002.","journal-title":"J Clin Oncol"},{"issue":"8","key":"789_CR71","doi-asserted-by":"publisher","first-page":"e600","DOI":"10.1016\/S2352-3026(23)00117-5","volume":"10","author":"L Xuan","year":"2023","unstructured":"Xuan L, Wang Y, Yang K, Shao R, Huang F, Fan Z, et al. Sorafenib maintenance after allogeneic haemopoietic stem-cell transplantation in patients with FLT3-ITD acute myeloid leukaemia: long-term follow-up of an open-label, multicentre, randomised, phase 3 trial. Lancet Haematol. 2023;10(8):e600\u201311.","journal-title":"Lancet Haematol"},{"issue":"5","key":"789_CR72","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1038\/s41409-020-01153-1","volume":"56","author":"RT Maziarz","year":"2021","unstructured":"Maziarz RT, Levis M, Patnaik MM, Scott BL, Mohan SR, Deol A, et al. Midostaurin after allogeneic stem cell transplant in patients with FLT3-internal tandem duplication-positive acute myeloid leukemia. Bone Marrow Transpl. 2021;56(5):1180\u20139.","journal-title":"Bone Marrow Transpl"},{"issue":"18","key":"789_CR73","doi-asserted-by":"publisher","first-page":"5345","DOI":"10.1182\/bloodadvances.2022007223","volume":"6","author":"H Dohner","year":"2022","unstructured":"Dohner H, Weber D, Krzykalla J, Fiedler W, Wulf G, Salih H, et al. Midostaurin plus intensive chemotherapy for younger and older patients with AML and FLT3 internal tandem duplications. Blood Adv. 2022;6(18):5345\u201355.","journal-title":"Blood Adv"},{"issue":"15","key":"789_CR74","doi-asserted-by":"publisher","first-page":"1766","DOI":"10.1200\/JCO.23.02474","volume":"42","author":"MJ Levis","year":"2024","unstructured":"Levis MJ, Hamadani M, Logan B, Jones RJ, Singh AK, Litzow M, et al. Gilteritinib as Post-Transplant Maintenance for AML With Internal Tandem Duplication Mutation of FLT3. J Clin Oncol. 2024;42(15):1766\u201375.","journal-title":"J Clin Oncol"},{"issue":"20","key":"789_CR75","doi-asserted-by":"publisher","first-page":"5123","DOI":"10.1182\/bloodadvances.2025016306","volume":"9","author":"MJ Levis","year":"2025","unstructured":"Levis MJ, Hamadani M, Logan BR, Jones RJ, Singh AK, Litzow MR, et al. Impact of transplant conditioning, NPM1 mutations, and measurable residual disease in FLT3-ITD acute myeloid leukemia. Blood Adv. 2025;9(20):5123\u201333.","journal-title":"Blood Adv"},{"issue":"9","key":"789_CR76","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1182\/blood.2019002959","volume":"135","author":"R Dillon","year":"2020","unstructured":"Dillon R, Hills R, Freeman S, Potter N, Jovanovic J, Ivey A, et al. Molecular MRD status and outcome after transplantation in NPM1-mutated AML. Blood. 2020;135(9):680\u20138.","journal-title":"Blood"},{"issue":"1","key":"789_CR77","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1038\/leu.2014.173","volume":"29","author":"RB Walter","year":"2015","unstructured":"Walter RB, Gyurkocza B, Storer BE, Godwin CD, Pagel JM, Buckley SA, et al. Comparison of minimal residual disease as outcome predictor for AML patients in first complete remission undergoing myeloablative or nonmyeloablative allogeneic hematopoietic cell transplantation. Leukemia. 2015;29(1):137\u201344.","journal-title":"Leukemia"},{"issue":"16","key":"789_CR78","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1182\/blood-2018-02-829911","volume":"132","author":"F Thol","year":"2018","unstructured":"Thol F, Gabdoulline R, Liebich A, Klement P, Schiller J, Kandziora C, et al. Measurable residual disease monitoring by NGS before allogeneic hematopoietic cell transplantation in AML. Blood. 2018;132(16):1703\u201313.","journal-title":"Blood"},{"issue":"11","key":"789_CR79","doi-asserted-by":"publisher","first-page":"2173","DOI":"10.1007\/s00277-018-3419-1","volume":"97","author":"T Konuma","year":"2018","unstructured":"Konuma T, Mizuno S, Kondo T, Yamaguchi H, Fukuda T, Uchida N, et al. Allogeneic hematopoietic cell transplantation in adult acute myeloid leukemia with 11q23 abnormality: a retrospective study of the Adult Acute Myeloid Leukemia Working Group of the Japan Society for Hematopoietic Cell Transplantation (JSHCT). Ann Hematol. 2018;97(11):2173\u201383.","journal-title":"Ann Hematol"},{"issue":"1","key":"789_CR80","doi-asserted-by":"publisher","first-page":"110","DOI":"10.3324\/haematol.2016.144253","volume":"102","author":"B Oran","year":"2017","unstructured":"Oran B, Jorgensen JL, Marin D, Wang S, Ahmed S, Alousi AM, et al. Pre-transplantation minimal residual disease with cytogenetic and molecular diagnostic features improves risk stratification in acute myeloid leukemia. Haematologica. 2017;102(1):110\u20137.","journal-title":"Haematologica"},{"issue":"5","key":"789_CR81","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/nrg.2017.117","volume":"19","author":"JJ Salk","year":"2018","unstructured":"Salk JJ, Schmitt MW, Loeb LA. Enhancing the accuracy of next-generation sequencing for detecting rare and subclonal mutations. Nat Rev Genet. 2018;19(5):269\u201385.","journal-title":"Nat Rev Genet"},{"key":"789_CR82","doi-asserted-by":"crossref","unstructured":"Weeks LD, Niroula A, Neuberg D, Wong W, Lindsley RC, Luskin M et al. Prediction of risk for myeloid malignancy in clonal hematopoiesis. NEJM Evid. 2023;2(5).","DOI":"10.1056\/EVIDoa2200310"},{"issue":"8","key":"789_CR83","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1182\/bloodadvances.2018015925","volume":"2","author":"MJ Levis","year":"2018","unstructured":"Levis MJ, Perl AE, Altman JK, Gocke CD, Bahceci E, Hill J, et al. A next-generation sequencing-based assay for minimal residual disease assessment in AML patients with FLT3-ITD mutations. Blood Adv. 2018;2(8):825\u201331.","journal-title":"Blood Adv"},{"issue":"10","key":"789_CR84","doi-asserted-by":"publisher","first-page":"2535","DOI":"10.1038\/s41375-019-0483-z","volume":"33","author":"TJ Blatte","year":"2019","unstructured":"Blatte TJ, Schmalbrock LK, Skambraks S, Lux S, Cocciardi S, Dolnik A, et al. getITD for FLT3-ITD-based MRD monitoring in AML. Leukemia. 2019;33(10):2535\u20139.","journal-title":"Leukemia"},{"issue":"22","key":"789_CR85","doi-asserted-by":"publisher","first-page":"2407","DOI":"10.1182\/blood.2022016567","volume":"140","author":"S Loo","year":"2022","unstructured":"Loo S, Dillon R, Ivey A, Anstee NS, Othman J, Tiong IS, et al. Pretransplant FLT3-ITD MRD assessed by high-sensitivity PCR-NGS determines posttransplant clinical outcome. Blood. 2022;140(22):2407\u201311.","journal-title":"Blood"},{"issue":"4","key":"789_CR86","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1200\/JCO.22.00715","volume":"41","author":"T Grob","year":"2023","unstructured":"Grob T, Sanders MA, Vonk CM, Kavelaars FG, Rijken M, Hanekamp DW, et al. Prognostic Value of FLT3-Internal Tandem Duplication Residual Disease in Acute Myeloid Leukemia. J Clin Oncol. 2023;41(4):756\u201365.","journal-title":"J Clin Oncol"},{"issue":"8","key":"789_CR87","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1001\/jamaoncol.2024.0985","volume":"10","author":"LW Dillon","year":"2024","unstructured":"Dillon LW, Gui G, Ravindra N, Andrew G, Mukherjee D, Wong ZC, et al. Measurable Residual FLT3 Internal Tandem Duplication Before Allogeneic Transplant for Acute Myeloid Leukemia. JAMA Oncol. 2024;10(8):1104\u201310.","journal-title":"JAMA Oncol"},{"key":"789_CR88","first-page":"4282","volume":"144","author":"MH Lee","year":"2024","unstructured":"Lee MH, McCall W, Cwykiel J, Lin C, Madarang E, Watts JM, et al. Real-world treatment patterns and effectiveness of midostaurin versus quizartinib in FLT3-ITD mutated acute myeloid leukemia undergoing intensive induction. Blood_supplement 1. 2024;144:4282.","journal-title":"Blood_supplement 1"},{"issue":"26","key":"789_CR89","doi-asserted-by":"publisher","first-page":"4236","DOI":"10.1200\/JCO.22.02721","volume":"41","author":"KW Pratz","year":"2023","unstructured":"Pratz KW, Cherry M, Altman JK, Cooper BW, Podoltsev NA, Cruz JC, et al. Gilteritinib in Combination With Induction and Consolidation Chemotherapy and as Maintenance Therapy: A Phase IB Study in Patients With Newly Diagnosed AML. J Clin Oncol. 2023;41(26):4236\u201346.","journal-title":"J Clin Oncol"},{"issue":"16suppl","key":"789_CR90","doi-asserted-by":"publisher","first-page":"e19036","DOI":"10.1200\/JCO.2022.40.16_suppl.e19036","volume":"40","author":"T Abuasab","year":"2022","unstructured":"Abuasab T, Kantarjian HM, Garcia-Manero G, Bravo GM, Valero YA, Daver NG, et al. Phase II study of cladribine, idarubicin, cytarabine (CLIA) plus gilteritinib in patients (pts) with FLT3 mutated acute myeloid leukemia (AML). J Clin Oncol. 2022;40(16suppl):e19036\u2013e.","journal-title":"J Clin Oncol"},{"issue":"7","key":"789_CR91","doi-asserted-by":"publisher","first-page":"2144","DOI":"10.1182\/bloodadvances.2021006489","volume":"6","author":"CC Smith","year":"2022","unstructured":"Smith CC, Levis MJ, Perl AE, Hill JE, Rosales M, Bahceci E. Molecular profile of FLT3-mutated relapsed\/refractory patients with AML in the phase 3 ADMIRAL study of gilteritinib. Blood Adv. 2022;6(7):2144\u201355.","journal-title":"Blood Adv"},{"key":"789_CR92","first-page":"e18522","volume":"43","author":"A Rajendra","year":"2025","unstructured":"Rajendra A, Smith E, Perusini MA, Tang K, Atenafu E, Bankar A, et al. Who benefits from gilteritinib combination therapy amongst FLT3mut R\/R AML? Genomic insights. J Clin Oncol_Suppl. 2025;43:e18522.","journal-title":"J Clin Oncol_Suppl"},{"key":"789_CR93","doi-asserted-by":"crossref","unstructured":"Mo S, Ambinder A, DeZern A, Smith BD, Fuchs E, Ghiaur G et al. DNMT3A, NPM1, and FLT3-ITD triple-mutated AML has a favorable prognosis in the era of FLT3 inhibitors. Blood_Supplement 1. 2025.","DOI":"10.1182\/blood-2025-1710"},{"issue":"2","key":"789_CR94","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1200\/JCO.2016.67.1875","volume":"35","author":"M Balsat","year":"2017","unstructured":"Balsat M, Renneville A, Thomas X, de Botton S, Caillot D, Marceau A, et al. Postinduction Minimal Residual Disease Predicts Outcome and Benefit From Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia With NPM1 Mutation: A Study by the Acute Leukemia French Association Group. J Clin Oncol. 2017;35(2):185\u201393.","journal-title":"J Clin Oncol"},{"issue":"19","key":"789_CR95","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.1182\/blood.2023023096","volume":"143","author":"J Othman","year":"2024","unstructured":"Othman J, Potter N, Ivey A, Jovanovic J, Runglall M, Freeman SD, et al. Postinduction molecular MRD identifies patients with NPM1 AML who benefit from allogeneic transplant in first remission. Blood. 2024;143(19):1931\u20136.","journal-title":"Blood"},{"issue":"10","key":"789_CR96","doi-asserted-by":"publisher","first-page":"2066","DOI":"10.1038\/s41375-023-01994-x","volume":"37","author":"J Othman","year":"2023","unstructured":"Othman J, Potter N, Mokretar K, Taussig D, Khan A, Krishnamurthy P, et al. FLT3 inhibitors as MRD-guided salvage treatment for molecular failure in FLT3 mutated AML. Leukemia. 2023;37(10):2066\u201372.","journal-title":"Leukemia"}],"container-title":["Current Hematologic Malignancy Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-026-00789-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11899-026-00789-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-026-00789-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T23:23:22Z","timestamp":1790897002000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11899-026-00789-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,1]]},"references-count":96,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["789"],"URL":"https:\/\/doi.org\/10.1007\/s11899-026-00789-y","relation":{},"ISSN":["1558-822X"],"issn-type":[{"value":"1558-822X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,1]]},"assertion":[{"value":"19 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":1,"name":"Ethics","label":"Human and Animal Rights and Informed Consent","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"J.F.M. declares that he has no conflict of interest. A.J.A. has received honoraria from Astellas and Daiichi Sankyo, serves on a steering committee for Servier, and has served on an advisory board for Melinta.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"22"}}